

Lorbrena[®] (Lorlatinib) Prior Authorization Form

Member Name: _____ Date of Birth: _____ Member ID#: _____

Drug Information

Pharmacy billing (NDC: _____) Start Date (or date of next dose): _____

Dose: _____ Regimen: _____

Billing Provider Information

Provider NPI: _____ Provider Name: _____

Provider Phone: _____ Provider Fax: _____

Prescriber Information

Prescriber NPI: _____ Prescriber Name: _____

Prescriber Phone: _____ Prescriber Fax: _____ Specialty: _____

Criteria**For Initial Authorization (Initial approval will be for the duration of 6 months):**

1. Diagnosis of non-small cell lung cancer (NSCLC)? Yes ___ No ___

A. If answer is 'yes' to question 1, please check all of the following that apply:

- Metastatic NSCLC
- Tumor expresses Anaplastic Lymphoma Kinase (ALK) translocation
- Lorlatinib will be used as a single-agent
- Lorlatinib will be used as first-line therapy
- Lorlatinib will be used as second-line therapy following disease progression on alectinib or ceritinib
- Lorlatinib will be used as third-line or greater therapy following disease progression on crizotinib and 1 other ALK inhibitor (i.e., ceritinib or alectinib)

If answer is 'no' to question 1, please provide diagnosis: _____

Additional Information: _____

For Continued Authorization:

1. Date of last dose: _____

2. Does member have any evidence of progressive disease while on lorlatinib? Yes ___ No ___

3. Has the member experienced adverse drug reactions related to lorlatinib therapy? Yes ___ No ___

If yes, please specify adverse reactions: _____

Additional Information: _____

Prescriber Signature: _____ Date: _____

I certify that the indicated treatment is medically necessary and all information is true and correct to the best of my knowledge.*Please do not send in chart notes. Specific information will be requested if necessary. Failure to complete this form in full will result in processing delays.***CONFIDENTIALITY NOTICE**

Fax completed prior authorization request form to 888-601-8461 or submit Electronic Prior Authorization through CoverMyMeds[®] or SureScripts. All requested data must be provided. Incomplete forms or forms without the chart notes will be returned. Pharmacy Coverage Guidelines are available at AetnaBetterHealth.com/Oklahoma.

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.